<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364039">
  <stage>Registered</stage>
  <submitdate>20/04/2013</submitdate>
  <approvaldate>1/08/2013</approvaldate>
  <actrnumber>ACTRN12613000848707</actrnumber>
  <trial_identification>
    <studytitle>Effects of Magnesium supplementation on metabolic control in type 2 diabetic subjects</studytitle>
    <scientifictitle>A randomised, placebo-controlled, double-blind, cross-over study of the effects of Magnesium supplementation on metabolic control in type 2 diabetic patients</scientifictitle>
    <utrn>U1111-1141-8501 </utrn>
    <trialacronym>None</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Metabolic control</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>One hundred diabetic patients were randomly assigned to receive two tablets Magnesium lactate 3.7 mmol (n=50) twice a day or placebo (n=50) during three months. After a washout period of three months each patient was then treated with the alternative regimen for an additional three months period. The treatment adherence will be assessed by measuring the urinary Magnesium clearance and counting the  tablets taken after each intervention period. The difference will be calculated as a percentage of the number that should have been taken. Non-adherence (&lt;80% or &gt;120%) will be treated as protocol violation.</interventions>
    <comparator>Placebo will be taken in the same frequency as the intervention treatment. 
The placebo tablet will have the same outward appearance as the intervention tablet.  </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Glycemic control as evaluated by glycated hemoglobin and fast glycemia</outcome>
      <timepoint>At baseline and after every intervention period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Insulin resistance estimated according to the Homeostasis Model Assessment (HOMA)</outcome>
      <timepoint>At baseline and after every intervention period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Type 2 diabetics with less than 15 years diagnosed.
2. Under treatment with diet, excercise or oral hypoglycemic agents. 
3.- Adequate renal function
4.- Absence of any type of cancer</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Chronic kidney failure
2. Use of diuretics
3. Chronic diarrhea
4. Alcoholism


</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The subjects will be recruited from those receiving attention in the diabetic clinic of Familial Medicine Unit 43 of the Mexican Social Security Institute. Subjects will be randomly assigned to receive Magnesium or placebo. Concealment by allocation schedule held independently by central administration staff.</concealment>
    <sequence>Randomization was achieved by the use of a computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>The primary endpoint was glycated haemoglobin. For detecting a difference of 10% or more between the two treatments with a power of 0.8 and a = 0.05, patients group size was calculated at 30. However 50 subjects by group will be selected to allow for non-compliance to therapy and assuming a dropout of 40%. Differences between groups will be estimated by two tailed paired Student t or Mann- Whitney test. Chi-squared test will be used for categoric variables. Differences will be considered to be statistically significant for P values lower than 0.05. Statistical analyses will be performed using SPSS IBM V 18 software.</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2012</anticipatedstartdate>
    <actualstartdate>1/05/2012</actualstartdate>
    <anticipatedenddate>1/08/2012</anticipatedenddate>
    <actualenddate>10/08/2012</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Tabasco</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Hospital General de Zona No 46. Instituto Mexicano del Seguro Social</primarysponsorname>
    <primarysponsoraddress>Carretera Villahermosa-Frontera SN.
Colonia Casa Blanca 86090
Villahermosa, Tabasco</primarysponsoraddress>
    <primarysponsorcountry>Mexico</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Universidad Juarez Autonoma de Tabasco</fundingname>
      <fundingaddress>Av. Universidad S/N
Zona de la Cultura
Colonia Magisterial C.P. 86040
Villahermosa, Centro, Tabasco</fundingaddress>
      <fundingcountry>Mexico</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a randomized, placebo-controlled, double blind, cross-over study to investigate the effects of Magnesium supplementation on metabolic control in type 2 diabetic patients. A group of 100 patients were iniitially selected and divided to receive two tablets Magnesium lactate 3.7 mmol twice a day (n=50) or placebo (n=50) during three months. After a washout period of three months, each patient was then treated with the alternatively regimen for an additional three months period. Glycemia,glycated hemoglobin, insulin, serum Magnesium and urine Magnesium excretion and other routine biochemical parameters will be performance at the baseline and after intervention period. Comparison between groups will be carried out by the paired Student t test or Mann Whitney test.     </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comite Local de Investigacion en Salud 2701</ethicname>
      <ethicaddress>Hospital General de Zona No 2
Francisco Trujillo Gurria SN
Colonia Pueblo Nuevo
Cardenas Tabasco C.P. 86500</ethicaddress>
      <ethicapprovaldate>18/01/2012</ethicapprovaldate>
      <hrec>R-2012-2701-1</hrec>
      <ethicsubmitdate />
      <ethiccountry>Mexico</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jorge Luis Ble Castillo</name>
      <address>UNIVERSIDAD JUAREZ AUTONOMA DE TABASCO
PROFESSOR-RESEARCHER
AV GREGORIO MENDEZ 2838-A
COLONIA TAMULTE DE LAS BARRANCAS 86150
VILLAHERMOSA, TABASCO
</address>
      <phone>(+52) 993 3145466</phone>
      <fax />
      <email>jorge.ble@ujat.mx</email>
      <country>Mexico</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Adrian Navarrete Cortes</name>
      <address>MEDICO NO-FAMILIAR (MEDICINA INTERNA)
INSTITUTO MEXICANO DEL SEGURO SOCIAL
AV UNIVERSIDAD S/N
COLONIA CASA BLANCA
VILLAHERMOSA TABASCO 86060

</address>
      <phone>(+52) 993 3517929</phone>
      <fax />
      <email>adrianavarrete@msn.com</email>
      <country>Mexico</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jorge Luis Ble Castillo</name>
      <address>UNIVERSIDAD JUAREZ AUTONOMA DE TABASCO
PROFESSOR-RESEARCHER
AV GREGORIO MENDEZ 2838-A
COLONIA TAMULTE DE LAS BARRANCAS 86150
VILLAHERMOSA, TABASCO


</address>
      <phone>(+52) 993 3145466</phone>
      <fax />
      <email>jorge.ble@ujat.mx</email>
      <country>Mexico</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Adrian Navarrete Cortes</name>
      <address>Mar Caribe 29
Residencial Rio Viejo
Villahermosa, Tabasco C.P. 86127</address>
      <phone>(+52) 993 3517929</phone>
      <fax />
      <email>adrianavarrete@msn.com</email>
      <country>Mexico</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>